Collaboration With Other Charities

We collaborate with other charities in the UK and globally, to advance DMD research. Our co-founder, Alex Johnson, sits on the board of UPPMD, United Parent Project Muscular Dystrophy, the global umbrella group for DMD patient organisations. 

Duchenne UK co-funds a number of clinical posts here in the UK with other DMD patient organisations and the Great Ormond Street Charity. Find out more here.

Our Partnerships

Our partnerships provide vital support to Duchenne UK, by fundraising for us and helping us to advocate to accelerate research. They share our ambition to fund the most promising research, no matter where it is in the world, and to do so with a vision to help bring that research out of the laboratory and into the clinic where it can help patients.

The Multiplier Effect 

Duchenne UK has a pioneering and ambitious research approach, which means that the money you raise for us can go further.  On certain projects, we create a 'multiplier effect'. Duchenne UK provides research spend to prove that a drug is ready for trial, which is then a catalyst for additional investment. By bridging the notorious valley of death in drug development, we are striving to bring promising therapies out of the laboratory and into the clinic where they can be tested on patients. 

Along with the Duchenne Research Fund, we invested $5million in a gene therapy project for Solid GT. That seed funding enabled them to raise $42m of private investment to fully fund further clinical trials.

We invested $1million of seed funding to co-fund the Phase I study of Vamorolone (VBP15). Following the trial's success, the company was able to raise $12m of government funding for the Phase II study of Vamorolone (VBP15).